Systemic Sclerosis Patients Have Activating Antibodies Targeting Both Endothelin Receptor Type A And Angiotensin Ii Type 1 Receptor Predicting Worse Prognosis. Anti-AT1R and anti-ETAR antibodies are a biomarker for severe disease and worse prognosis and could explain pathogenic features found in systemic sclerosis. The detection of these antibodies could identify SSc patients that might benefit from a receptor blockade or from a specific modulation of the antibody-receptor interaction. G. Riemekasten OP0162 EULAR 2007. (Also see: Causes of Scleroderma: Endothelin, Antibodies,and Prognosis)
Systemic Sclerosis Patients Have Activating Antibodies Targeting Both Endothelin Receptor Type A And Angiotensin Ii Type 1 Receptor
1 reply to this topic
Guest_Jude the Grouch_*
Posted 04 October 2007 - 09:32 AM
Posted 04 October 2007 - 12:57 PM
This is an interesting article. I take Letairis for PH. It's an endothelin receptor antagonist (ERA). I wonder if this is the same type of endothelin receptor blockade they refer to in the article?
You can deprive the body but the soul needs chocolate
my HMO makes me wear a helmet...